Clinical Consultation Sample Clauses

Clinical Consultation. 1. The Parties must establish policies and procedures for MCP and MHP to provide clinical consultations to each other regarding a Member’s mental illness, including consultation on diagnosis, treatment, and medications.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Clinical Consultation. Clinical Consultations consists of contact with one or more mental health professionals for the purpose of obtaining advice for the evaluation or management of a specific problem and for care coordination.
Sample 1Sample 2Sample 3
Clinical Consultation. The Department may provide professional consultations to the CSB upon request for clinically complex or difficult or medically complicated cases within resources available for this purpose in the Department or its facilities and as permitted under 45 CFR § 164.506 (c) (1) when individuals receiving services or their authorized representatives have requested second opinions and with valid authorizations that comply with the Human Rights Regulations and the HIPAA Privacy Rule or when staff of the CSB request such consultations for individuals it serves in the community, if it is not able to provide those second opinions or obtain this consultation within its resources.
Sample 1
Clinical Consultation. While on probation, Respondent shall consult 2 with a Board-approved forensic psychologist who will provide professional guidance and input 3 to Respondent with respect to ethics, clinical documentation/recordkeeping, importance of 4 professional consultation, testifying in legal proceedings, and any other topic deemed pertinent 5 by the forensic psychologist. The professional consultation shall be for a total period of four (4) 6 clock hours and may be at a frequency and duration determined by Respondent and consultant.
Sample 1
Clinical Consultation. Supplier’s Medical Directors and Scientific staff are available for development of alternative clinical pathways, standing orders and treatment monitoring. As with all cost reduction initiatives, these programs are available to all Participating Members. Cost savings vary from case to case.
Sample 1
Clinical Consultation. The Parties must establish policies and procedures to ensure that Members have access to clinical consultation, including consultation on medications, as well as clinical navigation support for patients and caregivers.
Sample 1
Clinical Consultation. 33.01 The existing program of clinical consultation will be improved upon during the term of the collective agreement. The form of the program’s expansion and content will be the subject of labour management dialogue. It is understood that the costs of improved clinical consultation will not exceed budget allocations and comply with funder guidelines.
Sample 1
AutoNDA by SimpleDocs
Clinical Consultation a. Contractor shall provide phone or email access to Client Agency physicians, clinical or medical staff to provide diagnostic insight and consultative services at no additional charge to Client Aency.
Sample 1

Related to Clinical Consultation

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Research Matters By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

Time is Money Join Law Insider Premium to draft better contracts faster.